The Motley Fool··Motley Fool TranscribingPulse Biosciences Advances Clinical Pipeline Despite Q1 Losses
Pulse Biosciences reported Q1 2025 net losses amid clinical expansion, with $119.3M cash and three devices progressing toward commercialization milestones.
PLSEclinical trialscommercialization